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Summary 
Inhalation of antigen in immunized mice induces an infiltration of eosinophils into the airways 
and  increased bronchial  hyperreactivity as  are  observed in  human  asthma.  We  employed a 
model of late-phase allergic pulmonary inflammation in mice to address the role ofleukotrienes 
(LT) in mediating airway eosinophilia and hyperreactivity to methacholine. Allergen intranasal 
challenge in  OVA-sensitized mice induced LTB4 and LTC  4 release into the airspace, wide- 
spread mucus occlusion of the airways, leukocytic infiltration of the airway tissue and broncho- 
alveolar  lavage  fluid  that  was  predominantly  eosinophils,  and  bronchial  hyperreactivity to 
methacholine.  Specific  inhibitors  of 5-1ipoxygenase  and  5-1ipoxygenase-activating protein 
(FLAP) blocked airway mucus release and infiltration by eosinophils indicating a key role for 
leukotrienes in these features of allergic pulmonary inflammation. The role of leukotrienes or 
eosinophils in mediating airway hyperresponsiveness to aeroailergen could not be established, 
however, in this murine model. 
I 
gE-receptor-mediated activation of mast ceils in the air- 
ways leads to oxygenation of arachidonic acid by 5-1ipoxy- 
genase  and generation of leukotrienes  (LT)  1 (1,  2).  LTB  4 
stimulates leukocyte chemotaxis (3), and the cysteinyl leu- 
kotrienes C4, D4, and g 4 induce bronchoconstriction (4, 5), 
mucus secretion (2)  and also  promote eosinophil chemo- 
taxis (6, 7) and hydrostatic pulmonary edema formation (8, 
9). After inhalation of specific allergen, allergic individuals 
may have both an early and late asthmatic response. Mast 
cell-derived bronchoconstrictors such as histamine (10) and 
cysteinyl leukotrienes (11,  12) likely contribute to the early 
bronchospastic response occurring within 30 min after al- 
lergen  challenge.  A  late  asthmatic  phase  occurs  sever~tl 
hours after exposure to allergen and is of prolonged dura- 
tion; an infiltration of the airway epithelium and bronchial 
fluid by eosinophils is characteristic of this phase (13,  14). 
The mouse  is  also  susceptible  to  development of IgE- 
mediated allergic responses. The late-phase influx of eosi- 
nophils is reproduced in a murine model in which allergic 
airway disease  develops after ovalbumin inhalation in mice 
i Abbreviations used in the paper: alum, aluminum potassium sulfate; BAL, 
bronchoalveolar  lavage; FLAP,  5-1ipoxygenase-activating  protein; i.n., in- 
tranasal; LT, leukotriene;  PAS, periodic  acid-Schiff. 
previously sensitized  to  ovalbumin intraperitoneally  (15). 
Increased  airway  responsiveness  to  methacholine  (16)  or 
acetylcholine (17) challenge also occurs in immunized mice 
after airway exposure to antigen.  In a mouse model of al- 
lergen-induced airway inflammation, we examined the role 
of leukotrienes in mediating airway eosinophil infiltration, 
mucus  release,  and  hyperresponsiveness to  methacholine. 
We report that leukotrienes are key mediators of the mucus 
release and eosinophil infiltration of the  airways, but not 
the airway hyperresponsiveness of the late phase asthma re- 
sponse. 
Materials and Methods 
Special Reagents.  Crystalline OVA was obtained  from Pierce 
Chem. Co.  (Rockford,  iL), aluminum  potassium sulfate (alum) 
from Sigma Chem. Co.  (St. Louis, MO), pyrogen-free distilled 
water from Baxter, Healthcare Corporation (Deerfield, IL), 0.9% 
sodium chloride (normal saline) from Lyphomed (Deerfield, IL), 
and Trappsol  TM  HPB-L100 (aqueous hydroxpropyl beta cyclodex- 
trin; 45 wt/vol% aqueous solution) from Cyclodextrin Technolo- 
gies Development Inc. (Gainesville, FL). The OVA (500 ~g/ml 
in normal saline) was mixed with equal volumes of 10% (wt/vol) 
alum in distilled water. The mixture (pH 6.5 using 10 N NaOH) 
after incubation for 60 rain at room temperature underwent cen- 
trifugation at 750 g for 5 min; the pellet was resuspended to the 
original volume in distilled water and used within 1 h. 
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[b]thien-2-ylethyl]-N-hydroxyurea) (18)  was kindly provided by 
Drs. Randy L. Bell and George W. Carter (Abbott Laboratories, 
Abbott Park, IL). The selective 5-1ipoxygenase-activating  protein 
(FLAP)  inhibitor MK-886  (L-663,536;3-[1-(4-chlorbenzyl)3-t- 
butyl-thio-t-isopropyl-indol-2-yl]-2-2-dlmethylpropanoic  acid)  (19, 
20)  was  generously provided by Dr. Anthony Ford-Hutchinson 
(Merck  Frosst Centre for  Therapeutic Research,  Pointe Claire- 
Dorval, Qutbec, Canada). Zileuton was dissolved in TrappsolT~; 
MK-886 was  dissolved in dimethylsulfoxide (DMSO)  and then 
diluted in normal saline, pH 7.0. 
Animals.  All animal use protocols were approved by the Uni- 
versity of Washington Animal Care Committee. Female BALB/c 
mice  (6-8 wk of age at purchase;  D  and K,  Seattle,  WA)  were 
housed under conventional conditions for the studies. 
Allergen  Immunization~Challenge  Protocol.  Mice  received  an 
i.p. injection of 0.2 ml (100 ~g)  of OVA complexed with alum 
on day 0 and 14. On days 14, 25, 26, and 27, mice were anesthe- 
tized  with  0.2  nd  i.p.  of ketamine  (0.44  mg/ml)/xylazine (6.3 
mg/ml) in normal saline before receiving an intranasal (i.n.) dose 
of 100 lag OVA in 0.05 ml normal saline on day 14 and an i.n. 
dose of 50 lag OVA in 0.05 ml normal saline on days 25, 26, and 
27. Two control groups were used. The first group received nor- 
real saline with alum i.p. on days 0 and 14 and normal saline with- 
out alum i.n. on days 14, 25, 26, and 27.  The second group re- 
ceived OVA with alum i.p. on days 0 and 14, OVA without alum 
i.n. on clay 14, and normal saline alone on days 25, 26, and 27. 
Leukotriene  Inhibitor  and LYE)  4 Studies.  To  assess the  role  of 
5-1ipoxygenase products in airway inflammation, the 5-1ipoxyge- 
nase inhibitor zileuton (35 mg/kg) or the FLAP inhibitor MK-886 
(3 mg/kg)  were given i.p. 30 min before each i.n. challenge on 
days 25, 26, and 27. In one set of animals, zileuton was also given 
on days 0 and 14 (before i.p. OVA). Zileuton at 35 mg/kg inhibits 
cysteinyl leukotriene release by -,~95% in passively sensitized rats 
given BSA antigen i.p.  (18).  MK-886 at 3  mg/kg inhibits LTB4 
biosynthesis by 98% in inflamed rat paws given subplantar injec- 
tion of thioglycollate followed  6  h  later by calcium ionophore 
A23187 treatment (20). 
To  assess the  role  of leukotrienes  in  airway  mucus  release, 
non-immunized  mice received 0.1 ml i.n. of either LTD  4 (2.5  txg 
in 1% ethanol) or vehicle (1% ethanol). After 60 rain, lung tissue 
was obtained and stained with hematoxylin and eosin as described 
below. 
Pulmonary  Function  Testing.  On day 28, 24 h  after the last i.n. 
administration of either normal saline or OVA, pulmonary me- 
chanics  to  intravenous infusions  of methacholine  were  deter- 
mined in mice in vivo by a plethysmographic method modified 
from  that  previously described  by Amdur  and  Mead  (21)  and 
Martin et al.  (22).  After pentobarbital (70-90 mg/kg,  i.p.)  anes- 
thesia,  the mice underwent thoracotomy with wide opening of 
the thorax, jugular vein cannulation with 8 cm silastic tubing, and 
tracheal intubation with an angled 18-gauge blunt needle. In one 
compartment (0.25 ml dead space)  of a two chamber whole body 
plethysmograph, the animal was placed in a supine position and 
connected to  a  Harvard ventilator.  Normal  arterial blood gases 
were maintained by the following minute ventilation: tidal vol- 
ume =  0.2 ml/20 gm, frequency 120 breaths/rain, positive end- 
expiratory pressure 2.5-3 cm H20  (23).  Constant temperature in 
the plethysmograph was maintained by a copper mesh heat sink. 
Since the plethysmograph was a closed system, the change in box 
pressure (Pbo~) of the first chamber (measured by a sensitive trans- 
ducer  [_+0.7  cm HgO])  represented the  change in lung volume 
(Avol  =  Pbox)  of the  mouse;  Pbox  is  equivalent to  lung pleural 
pressure. The system was calibrated by syringe delivery of 0.2 ml 
air at a frequency of",q20/min. Rapid ambient pressure swings 
(e.g., door openings) in the first chamber were offset by reference 
of the transducer to the pressure in the second chamber. A micro- 
valve with a  time constant '~4.5 s was placed between the  two 
compartments to correct for any temperature increases in the first 
chamber resulting from  the  body heat  of the animal. A  second 
microvalve with a longer time constant ("~11 s) was open to am- 
bient air to keep mean Pbox close to zero.  Pressure movements at 
the opening of the tracheal tube (P.~w) were measured by another 
transducer, referenced to Pbox to determine transpulmonary pres- 
sure (Ptp ---=  Paw -  Pbox)" 
After initial inflation to  a  P,w  of 30--35  cm  H20,  the  lungs 
were inflated at least once 1-2 min before each measurement to 
prevent partial collapse. An analog-to-digital data acquisition sys- 
tem (Strawberry Tree  |  was employed to sample Ptp  and Pbox at 
5-ms intervals. The digital Ptp data were then offset  by 15 ms to 
bring it into phase with the Pbox signal as determined by making a 
step change in PUo,  with no animal connected to the tracheal can- 
nula.  A  smoothing function was  applied  to  dampen  the  back- 
ground noise in Pbox 
(X-I)  +2X+.(X+  4  1)], 
where X is the flow at a specific time point). The change in vol- 
ume from point-to-point/5 ms was used to calculate flow. 
Data from seven consecutive breaths collected three times dur- 
ing the first  10 min were used to calculate basal pulmonary func- 
tion. Methacholine was  then infused by hand delivery into the 
jugular vein over 10 s at increasing concentrations (3,  12, 48, 120, 
and 480  mg/kg)  after  10  min of ventilation. Intervals of 1.5-3 
min between injections enabled pulmonary function to return to 
basal levels. Resistance (R), lung conductance (G  L =  l/R),  and 
dynamic compliance (Cdw) were determined for both the control 
period and the peak response to each methacholine concentration 
that was seen during 30 s of monitoring post-injection to bracket 
the  peak  response.  Tracheal  tube  resistance  (0.63  cm  HgO  X 
ml-T ￿  s) was subtracted from all airway resistance measurements. 
The difference in P~p and air flow at mid-tidal volume on inflation 
and  deflation was  used to  calculate  R.  Cdyn was  calculated as the 
change in tidal volume divided by the difference between Ptp at 
end-inspiration and  end-expiration when  flow  is  zero  (Cay, = 
dIVt/Ap~p).  At  each  methacholine  concentration,  GL  and  Cay, 
were  expressed as the percent of basal value. The methacholine 
dose which reduced  GL and Car  n to  75  and 50% of the  control 
values (ED2s and ED50, respectively) was calculated from the log 
dose-peak response curves and expressed  as the geometric mean + 
log SD  At the  completion of pulmonary function testing,  each 
mouse was exsanguinated by cardiac puncture. 
Bronchoalveolar Lavage.  After  tying  off  the  left  lung  at  the 
mainstem bronchus, the right lung was lavaged three times with 
0.4 ml of normal saline. Bronchoalveolar lavage (BAL)  fluid cells 
from a 0.05-ml aliquot of the pooled sample were counted using 
a hemocytometer and the remaining fluid centrifuged at 4~  for 
10  rain  at  200 g.  The  supematant was  stored  at  -70~  until 
eicosanoid analyses were performed. After resuspension of the cell 
pellet  in  normal  saline  containing 10%  BSA,  BAL  cell  smears 
were made on glass slides.  To stain eosinophils, dried slides were 
stained with Discombe's diluting fluid (0.05 % aqueous eosin and 
5%  [vol/vol] acetone in distilled water)  (24)  for 5-8 rain, rinsed 
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with water for 0.5 min, and counterstained with 0.07% methyl- 
ene blue for 2 min. 
Lung Histology.  After BAL,  the trachea  and left lung (upper 
and lower lobes) were obtained and fixed in Carnoy's solution at 
20~  for N15 h. After embedding in paraffin, the tissues were cut 
into  5-p,m sections  and stained with Discombe's solution and 
counter-stained with  methylene blue as  described  above.  The 
eosinophil number per unit airway area  (2,200  I~m  2) was deter- 
mined by morphometry as previously described  (25, 26). Airway 
mucus was identified by the following staining methods: methyl- 
ene blue, hematoxylin and eosin,  mucicarmine, toluidine blue, 
alcian blue, and alcian blue/periodic acid-Schiff (PAS) reaction 
(27, 28). Mucin was stained with mucicarmine solution; metanil 
yellow counterstain was  employed.  Mucin and sialic acid-rich 
nonsulfated mucosubstances were stained metachromatically with 
toluidine blue,  pH  4.5.  Acidic  mucin and  sulfated  mucosub- 
stances were  stained with alcian blue, pH  2.5;  nuclear fast red 
counterstain was used.  Neutral and acidic mucosubstances were 
identified by alcian blue, pH 2.5,  and PAS reaction. The degree 
of mucus plugging of the airways (0.5-0.8 mm in diameter)  was 
also assessed by morphometry. The percent occlusion of airway 
diameter by mucus was classified on a semiquantitative scale from 
0 to + + + + +  as described in the Figure Legends. The histologic 
and  morphometric  analyses  were  performed  by  individuals 
blinded to the protocol design. 
Assay of Airway Mucus Glycoproteins.  Mucus  glycoproteins in 
BAL fluid were assayed by slot blotting and PAS staining as previ- 
ously described (29, 30). Nitrocellulose membranes (0.2-p,m pore 
size; Schleicher  & Schuell,  Keene, NH) were wetted in distilled 
water and then in normal saline before placement in a Minifold II 
72-well slot blot apparatus (Schleicher & Schuell). The BAL fluid 
samples (0.05 ml) and aliquots (0.05-0.75 ml) of a stock solution 
(2 p,g/ml)  of human respiratory  mucin glycoprotein (31) (kindly 
provided by Dr. James  Shelhamer)  were blotted onto the nitro- 
cellulose membranes by water suction vacuum, and mucus glyco- 
proteins were visualized by PAS reaction. Reflectance densitom- 
etry was performed to  quantitate the PAS staining.  The images 
were captured and digitized  by a ScanJet Ilcx Scanner with HP 
DeskScan  II software  (Microsoft |  Windows  TM  Version)  (Hewlett 
Packard,  Palo  Alto, CA). This system was linked to a Dell Di- 
mension XPS P90 computer (Dell Corporation, Austin, TX) em- 
ploying Image-Pro  |  Plus, Version 1.1  for Windows  TM  software 
(Media  Cybernetics, Silver  Spring,  MD).  The images  were  as- 
sessed on a 256 gray level scale using a Dell UltraScan 17ES mon- 
itor with  extra  high-resolution graphics  mode  (1,280  ￿  1,024 
pixels,  78.9-kHz horizontal scanning frequency, 74-Hz vertical 
scanning frequency).  The integrated intensity of the PAS reactiv- 
ity of the  BAL  samples was  quantitated by comparison to  the 
standard  curve  for  human respiratory  mucin as  previously de- 
scribed (29). 
Specific Antibody Levels.  Previous  studies  have  demonstrated 
that i.p.  immunization with OVA results in detectable  levels of 
OVA-specific IgE  in the blood of BALB/c mice (32). Indirect 
ELISA was employed to determine OVA-specific  IgE serum anti- 
body titers.  ELISA  plates  (ICN,  Costa  Mesa,  CA) were coated 
with OVA (20 mg/rnl) diluted in 0.1 M NaHCO3 buffer, pH 8.3 
and incubated at  4~  for  18 h.  After  washing three  times,  the 
plates were incubated with 1% BSA in PBS, pH 7.4, at 37~  for 2 h. 
Serial dilutions of the serum samples in 1% BSA/PBS buffer were 
added to the plates and incubated at 4~  for 18 h before washing 
again. The wells were incubated with HRP-conjugated rat anti- 
mouse IgE monoclonal antibody (PharMingen, San Diego, CA) 
r 
== 
60. 
50. 
40- 
30- 
20- 
10- 
70- 
Saline  OVA  Zileuton/OVA 
60. 
50- 
40- 
30' 
20 
10 
0 
a. LTC  4 
"p <  0.03 
Saline  OVA  Zileuton/OVA 
Figure  1.  5-Lipoxygenase  inhibition  blocks leukotriene  release in OVA- 
immunized/challenged  mice. BAL fluid was obtained on day 28 from 
sham-sensitized mice receiving i.n. saline challenge (Saline; n =  8), and 
OVA-sensitized  mice either untreated (OVA; n = 7) or treated (Zileuton/ 
OVA; n =  7) with the 5-1ipoxygenase  inhibitor zileuton 30 rain before 
i.n. OVA challenge  on day 25, 26, and 27. The BAL fluid was assayed for 
(A) LTB4 and (B) LTC4 as described in Materials and Methods. "P value, 
Zileuton/OVA versus OVA. 
diluted in 50% goat  serum (GIBCO BRL,  Gaithersburg,  MD)/ 
PBS buffer for 2 h  at room temperature. 3,3',5,5'-tetramethyl- 
benzidine substrate  was  used  to  develop the  wells  with  absor- 
bance determined at 610 nm. The internal standard in each assay 
consisted of pooled serum from OVA-immunized  BALB/c mice. 
Eicosanoid Assays.  BAL fluid was assayed for LTB4 and LTC~ 
in duplicate  by RIA (33). LTB  4 was assayed using a commercial 
[3H]LTB4 RIA kit (NEN Research Products, Boston, MA). The 
detection limit for LTB  4 was 12.5 pg/0.1  ml sample. LTC  4 was 
obtained from  Cayman  Chemical  Co.  (Ann Arbor,  MI)  and 
[3H]LTC4 from NEN Research Products (Boston,  MA). Rabbit 
antisera against LTC  4 (kindly provided by Drs. Robert W. Egan 
and John L.  Humes, Merck Institute for Therapeutic Research, 
Rahway, NJ)  had the following cross-reactivities  at B/Bo  50%: 
(5S, 6R)-LTC4, 100%}; LTD4, 43%; 11-trans-LTD 4, 47%; LTE4, 
6%;  LTF  4,  50%; (5R,  6R)-LTC4,  100%; (5S, 6S)-LTC4,  1.7%; 
(SR,  5S)-LTC  4,  0.7%;  LTC4-sulfone, 10%; LTD4-sulfone, 7%; 
LTE4-sulfone,  0.4%; LTF4-sulfone,  1.0%; and LTB4, (5S, 6R)- 
7,8,9,10,11,12,14,15-octahydro-LTC4,  PGE2, PGF2~, glutathione, 
5-HETE, and arachidonic  acid each <0.2% (34). The LTC  4 RIA 
had a sensitivity of 20 pg/0.1 ml sample. 
Statistical Analyses.  The pulmonary function data were evalu- 
ated by analysis of variance (ANOVA) using the protected least 
significant difference method (Statview II, Abacus Concepts, Berke- 
ley,  CA). This method uses a multiple t statistic to  evaluate  all 
possible pairwise comparisons and is applicable for both equal and 
1485  Henderson et al. Figure 2.  Histologic evidence of airway inflammation in OVA-treated 
and  control  mice:  effect of 5-1ipoxygenase inhibition.  Lung  tissue  was 
obtained from sham-sensitized and saline-challenged mice (A), and OVA- 
mmmnized/challenged mice in the absence (B) or presence (C) of zileu- 
ton treatment. Lung sections were stained in Discombe's solution, coun- 
terstained  with  methylene blue,  and  examined by  light  microscopy as 
described in Materials and Methods. (A) The airway lumen (AL) is clear 
of mucus and cells  in  control mice. The bronchial epithelium is intact. 
Connective tissue cells but not leukocytes are present in the peribronchial 
interstitial space.  (B)  Large amounts of secreted mucus are identified in 
the lumen of the airways of the OVA-sensitized/challenged mice by me- 
thylene blue staining.  Massive infiltration of  the interstitial  tissue by eosino- 
phils  and  other inflammatory cells  is  noted  (arrows). (C)  Airway mucus 
release in the airway lumen (AL) is markedly reduced when the 5-1ipoxy- 
genase inhibitor zileuton is given before i.n. OVA. The infiltration of the 
interstitial tissue  by eosinophils is  also  reduced after zileuton  treatment 
compared to OVA-challenge alone (B). Bars,  100 txm. 
Figure 3.  Eosinophil infiltration of  lung tissue and BAL fluid in OVA- 
treated mice.  Lung  tissue  and BAL  fluid  cells  from  OVA-immunized/ 
challenged mice were stained for eosinophils as described in Fig. 2 B. (A) 
Eosinophils (arrows) are the predominant inflammatory cell in the intersti- 
tial tissue  of the airway. (B) Large accumulation of mucus (arrowheads) m 
the airway lumen is observed. Many goblet cells (*) are seen in the airway. 
Numerous eosinophils (arrows) are found in the mucus plug. (C)  The ma- 
lority of  the BAL fluid cells are eosinophils (arrows). Alveolar macrophages 
(arrowheads) are also observed. Bars,  (A) 50 Ixm; (B and C)  10 fxm. 
1486  Role of Leukotrienes in Allergic Airway Inflammation Figure  4.  Mucus occlusion of lower airways in OVA-treated mice. Lower lobe tissue of the left lung from OVA-immunized/challenged mice was 
stained for mucus by mucicarmine (A), toluidine blue (B), alcian blue (C), and alcian blue/PAS (/9) procedures as described in Materials and Methods. 
(A) Airway mucin is stained rose-red by mucicarmine, and interstitium is stained yellow by the metanil yellow counterstain. (B) Mucin and nonsulfated 
acidic mucosubstances are stained metachromatically red-purple by toluidine blue. (C) Acidic sulfated mucosubstances and mucins are stained blue by al- 
cian blue, and nuclei are stained pink-red by the nuclear fast red counterstain. (D) Acidic and neutral mucosubstances are stained magenta by alcian blue/ 
PAS. Bar, 100 p,m. 
1487  Henderson et al. unequal pair sizes. The other data are reported as the mean --- SE 
of the combined experiments. Differences were analyzed for sig- 
nificance (P <0.05) by Student's two-tailed t test for independent 
means. 
Results 
Allergen-Specific IgE Production.  OVA-specific IgE (14.9  -+ 
3.5 U/m1,  n  =  5) was detected on day 28  in the blood of 
mice  given i.p. OVA  and  alum on  day 0  and  14  and i.n. 
OVA  on  days  25,  26,  and  27.  In  contrast,  control  mice 
treated with i.p. saline and alum and i.n. saline (n -- 6) had 
no detectable anti-OVA IgE. 
Allergen-induced Eicosanoid Release in BAL Fluid.  BAL  fluid 
was obtained 24  h  after the third i.n. administration of ei- 
ther  OVA  or saline in  mice  that  had  received i.p.  either 
OVA  or  saline  respectively  and  assayed  for  eicosanoids. 
The BAL fluid levels of the 5-1ipoxygenase products LTB 4 
(Fig.  1  A)  and  LTC4  (Fig.  1  B)  were  3.4-fold  (P  <0.03 
compared to  saline)  and  5.0-fold  (P <0.05,  compared to 
saline)  higher  respectively in  the  OVA-immunized/chal- 
lenged  mice  than  in  the  mice  receiving saline  only.  The 
selective  5-1ipoxygenase  inhibitor  zileuton  given  30  min 
before i.n. challenge with OVA on day 25, 26, and 27 sig- 
nificantly inhibited  LTB 4 and  LTC 4 release  compared  to 
mice challenged with i.n. OVA in the absence of zileuton 
(Fig. 1). The levels of LTB 4 and LTC 4 in the BAL fluid of 
OVA-immunized/challenged  mice  treated  with  zileuton 
were not significantly different from those of the saline con- 
trol group (Fig. 1). 
Allergen-induced Airway Inflammation.  To assess allergen- 
induced airway inflammation histologically, lung tissue and 
BAL fluid were obtained on day 28, 24 h  after the last of 3 
sequential i.n. OVA challenges on days 25,  26,  and 27. By 
light  microscopy,  prominent  infiltration  of the  bronchial 
interstitium by eosinophils was  observed (Figs. 2  B  and  3 
A).  Eosinophil influx  into  the  bronchial epithelial mucus 
layer (Fig. 3 B) and the BAL fluid (Fig. 3  C) was also noted. 
63.6  +  3.2%  (n  =  10)  of the BAL fluid cells were eosino- 
phils in OVA-sensitized/challenged mice compared to 0.8  +_- 
0.3%  (n  =  10)  in  saline-challenged control animals  (P  = 
0.0001),  Mucus  occlusion of the  airways occurred in im- 
munized mice after bronchial challenge with OVA (Fig. 2 
B). Airway mucus release in both lower (Fig. 4) and upper 
(Fig.  5)  pulmonary  airways was  identified by  several his- 
tochemical  staining  procedures:  mucin  by  mucicarmine 
stain  (Figs.  4  A  and  5  A),  acidic  nonsulfated  mucosub- 
stances by toluidine blue (Figs. 4  B and 5 B), acidic sulfated 
mucosubstances  by  alcian  blue  (Figs.  4  C  and  5  C),  and 
neutral and acidic nmcosubstances by alcian blue/PAS re- 
action  (Figs.  4  D  and  5  D).  Airway lumen  occlusion by 
mucus  was  greater in the  smaller diameter airways. These 
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Figure 6.  Leukotriene inhibition blocks eosinophil infiltration of air- 
way tissue and BAL fluid in OVA-treated mice. (A) Lung tissue was ob- 
tained from sham-sensitized and saline-challenged mice (Saline; n =  8) 
and OVA-sensitized/challenged mice in the absence (OVA; n =  7)  or 
presence (Zileuton/OVA; n --- 7) of zileuton treatment. The number of 
eosinophils per unit area (2,220 Ixm  2) was determined by morphometric 
analysis. *P value, Zileuton/OVA versus OVA. (B) BAL fluid was ob- 
tained from sham-sensitized and saline-challenged mice (Saline; n =  3), 
and OVA-sensitized/challenged mice in the absence (OVA; n =  4) or 
presence (MK-886/OVA; n =  3) of treatment with the FLAP inhibitor 
MK-886. The number of eosinophils per total lavage fluid collected is 
shown. *P value, MK-886/OVA versus OVA. 
inflammatory changes were absent in i.n. saline-challenged 
control animals that had been treated i.p. with either saline 
(Fig. 2 A) or OVA (not shown) with alum. 
Leukotriene Inhibition  Blocks Eosinophil Infiltration and Mu- 
cus Accumulation in Airways.  5-Lipoxygenase  inhibition  by 
zileuton markedly reduced eosinophil influx into the lung 
tissue  and  BAL  fluid  of OVA-sensitized/challenged mice 
and  also prevented airway mucus  release in  these  animals 
(Fig. 2  C). 
Eosinophil Infiltration.  By morphometric analysis, the eosi- 
nophil influx into the lung interstitium was reduced 82% by 
zileuton treatment  (P <0.006  compared to OVA without 
zileuton)  (Fig.  6  A).  The  FLAP  inhibitor  MK-886  de- 
creased the number of eosinophils in the BAL fluid by 86% 
(P <0.0004  compared to  OVA without MK-886)  (Fig. 6 
Figure 5.  Mucus  release in upper airways in OVA-treated mice. Upper lobe lung sections from OVA-treated mice were stained histochemically for 
mucus as described in Fig. 4. The airways shown are larger in diameter and have a greater density of smooth muscle cells than the small airways seen in 
Fig. 4. (A) Mucicarmine staining (rose-red) of upper airway mucin is shown. (B) Metachromatic toluidine blue staining (red-purple) ofnonsulfated acidic 
mucosubstances and mucin is demonstrated. (C) Acidic sulfated mucosubstances, hyaluronic acid, and sialomucins are stained blue by alcian blue. (D) A1- 
clan blue/PAS staining (magenta) of neutral and acidic mucosubstances is shown. Bar, 200 Ixm. 
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Figure 7.  Effect  of 5-1ipoxygenase inhibition on nmcus accmnulation 
in the airways of OVA- treated and control naice. The percent distribu- 
tion of mucus occlusion of airways from sham-sensitized and saline-chal- 
lenged mice (Saline; n =  8), and OVA- sensitized/challenged mice in the 
absence (OVA; t~ =  7) or presence (Zileuton/OVA; n  =  7) of zileuton 
treatment.  Mucus occlusion of airway diameter was assayed morphomet- 
rically as follows: 0, no mucus; +, ~1()% occlusion; + +, ~30% occlu- 
sion;  +++,  ~50%  occlusion;  ++++,  ~"80% occlusion;  +++++, 
90-100% occlusion, l0 airways randomly distributed throughout  the left 
lung of each mouse were assessed for mucus occlusion morphometrically. 
B).  The  number of eosinophils in the BAL fluid from  the 
OVA-sensitized/challenged  mice  treated  with  the  FLAP 
inhibitor  (0.57  4-  0.11  X  105,  Fig.  6  B)  was  not  signifi- 
cantly different from  that  in either  sham-sensitized/saline- 
challenged (0.12  +  0.02  X  l0  s,  Fig.  6  B)  or OVA-immu- 
nized/saline-challenged  (0.16  +  0.03  ￿  not  shown) 
control  mice.  Zileuton similarly decreased  eosinophils re- 
covered  in  the  BAL  fluid  of OVA-sensitized/challenged 
mice by 91%  (P =  0.0128  compared  to  OVA without zi- 
leuton; data  not shown).  Vehicle  controls  (Trappsol  TM  for 
zileuton studies, DMSO  for MK-886 studies) did not affect 
the  lung  eosinophil  infiltration  observed  in  OVA  sensi- 
tized/challenged mice. 
Mucus Accumulation.  Cross-sections of the upper and lower 
lobes  of the  left  lung  of OVA-treated  and  control  mice 
were  examined by light microscopy for mucus accumula- 
tion in the airways. By morphometric  analysis, 68% of the 
airways of control mice treated with saline had no evidence 
of airway  mucus  release,  and  the  remainder  had  only  a 
small  mucus  layer  observed  (Fig,  7).  In  contrast,  OVA- 
inmmnized/challenged mice had morphologic evidence for 
widespread  mucus  plugging of the  airways.  The  majority 
(74%)  of the airways of the OVA-treated mice had at least 
30%  occlusion of the airway lumen by mucus; 22%  of the 
airways of these mice had 80%  or greater mucus occlusion 
(Fig.  7).  When  the  amount of mucus glycoprotein recov- 
ered in the BAL fluid was  quantitated  (Fig.  8),  a  sevenfold 
increase  in  airway  mucin  was  demonstrated  in  OVA- 
treated mice compared to control mice (P =  0.00001  OVA 
versus saline). Zileuton-treatment blocked the airway mu- 
cus release in the OVA-treated mice (Figs. 2  C  and 8),  The 
importance  of leukotrienes  in  airway  mucus  release  was 
further  demonstrated  by the  ability of LTD  4 administered 
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Figure  8.  5-Lipoxygenase  inhibition blocks  airway mucus  release in 
OVA-treated nfice. BAL fluid was obtained from sham-sensitized and sa- 
line-challenged  mice  (Saline; n  =  4)  and  OVA-sensitized/challenged 
mice in the absence (OVA; n =  4) or presence (Zileuton/OVA; n = 4) of 
zileuton  treatment,  BAL fluid (0.05 ml) was blotted onto nitrocellulose 
with mucin visualized by PAS reaction and quantitated by an image anal- 
ysis system as described in Materials and Methods.  For a standard curve, 
human respiratory nmcin (0.05-0.75  ml, 2 b~g/ml) was similarly assayed. 
* value, Zileuton/OVA versus OVA. 
exogenously by the i.n.  route  to  induce airway mucus re- 
lease (Fig. 9). 
5-Lipoxygenase  Inhibition  Does  Not  Alter  Allergen-induced 
Airway Hyperreactivity  to Methacholine.  Mice  receiving  i.p. 
and i.n.  OVA had increased airway reactivity compared  to 
control  mice  receiving saline;  the  OVA-treated  mice  re- 
quired  significantly lower  concentrations  of methacholine 
to decrease GL (Fig.  10 A) and Cay, (Fig.  10 B) than control 
mice that had been sham-sensitized and chaUenged with sa- 
line  (Table  1)  or  OVA-immunized/saline challenged  (not 
shown).  Although  leukotriene  inhibition blocked  airway 
eosinophil influx and mucus release in OVA-treated mice, 
zileuton given before  OVA  on day 25,  26,  and 27  did not 
reduce airway hyperresponsiveness to methacholine in these 
Figure 9.  LTD  4 induces airway mucus release. Upper airway tissue was 
obtained 60 rain after i.n. challenge with LTD 4 (2.5  btg) and stained with 
hematoxylin and eosin. Mucus deposition (arrou:~)  in the airway lumen (L) 
is shown. Airway mucus release was not observed in mice receiving i.n. 
vehicle alone (not shown). Bar, 200 bun. 
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Figure  10.  5-Lipoxygenase  inhibition does not  alter methacholine- 
induced airway responsiveness  in OVA-treated mice. Airway  responsive- 
ness to  increasing concentrations of methacholine was  determined in 
sham-sensitized and saline-challenged  mice (Saline; n =  19), and OVA- 
sensitized/cballenged  mice in the absence (OVA; n =  18) or presence 
(Zih,  uton/OVA;  n =  17) of zileuton treatment. (A) Airway conductance 
animals (Fig. 10, Table 1). No significant difference in basal 
conductance or compliance was observed among the three 
groups  (Table  1).  Zileuton treatment on day 0  and 14 in 
addition to days 25, 26, and 27 did not alter methacholine- 
induced lung responses (data not shown). The FLAP inhib- 
itor MK-886 when given 30 rain before i.n. OVA-challenge 
on days 25, 26, and 27 also failed to block the increased air- 
way response to methacholine (data not shown). 
Discussion 
Our studies demonstrate that leukotrienes are key medi- 
ators of allergen-induced airway eosinophil infiltration and 
mucus release but not the increased airway responsiveness 
to  methacholine occurring in a  mouse  model of asthma. 
BALB/c mice given i.p.  OVA in alum twice over a  14-d 
period followed by three i.n. doses of OVA on days 25, 26, 
and 27  of the  protocol  developed OVA-specific IgE  and 
histologic  and  physiologic  findings  mimicking  human 
asthma. In mice examined 24 h  after the last i.n. adminis- 
tration of OVA on day 28, eosinophils were the predomi- 
nant inflammatory cell  in both  the  lung interstitial tissue 
and BAL fluid. Mucus occlusion of the airway lumen (lower 
>upper airways)  in the  OVA-treated mice was  a  promi- 
nent feature of this late-phase allergen-induced inflamma- 
tory  process.  Further,  in  vivo  pulmonary  function  tests 
showed that the OVA-immunized/challenged  mice repro- 
ducibly developed increased airway responsiveness to intra- 
venous methacholine compared to controls. 
In vitro and in vivo studies in animals and humans have 
suggested that leukotrienes play a role in the pathogenesis 
of allergic airway inflammation. Nocturnal levels of LTB  4 
(Gt) and (B)  dynamic lung compliance (Cdy n  ) were calculated as de- 
scribed in Materials and Methods. The data are mean --- SE. *P <0.05 by 
ANOVA, Saline  versus the OVA and Zileuton/OVA groups. 
Table 1.  Pulmonary Mechanics  to Methacholine  in OVA-treated Mice: Effect of Leukotriene Inhibition 
Conductance (GL) 
EDs<~ methacholine 
Dynamic compliance (Cax,) 
EDs~ methacholine 
Group  Basal  Geometric mean  Log SD  Basal  Geometric mean  Log SD 
ml/s X  cm HeO  txg/~r  ml/s X  cm H20  Ixg/kg 
Saline  1.30 +  0.04  104"  0.29  0.028  •  0.001  277*  0.29 
OVA  1.22 +__ 0.03  56  0.20  0.026  •  0.001  107  0.19 
Ziteuton/OVA  1.24 -  0.03  54  0.23  0.026 __ 0.001  111  0.21 
Data represent mean + SE. GL and Cdy, were determined in sham-sensitized  and saline-challenged  mice (Saline, n =  19), and OVA-sensitized/chal- 
lenged mice in the absence (OVA; n =  18) or presence (Zileuton/OVA; n =  18) of zileuton treatment. 
*P <0.05 vs both other groups (by ANOVA using the protected least significant  difference  method). 
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patients with nocturnal asthma compared to normal control 
subjects (35).  Increased levels ofLTB  4 and LTC  4 are recov- 
ered in  the  BAL fluid  (11,  12)  and  elevated levels of the 
LTC4 metabolite LTE  4 are detected in the urine  (36)  after 
endobronchial challenge with specific allergen compared to 
prechallenge  levels  of these  eicosanoids.  Similarly,  in  this 
mouse model of asthma, we found that levels of LTB  4 and 
LTC  4 were significantly increased in BAL fluid after airway 
allergen challenge; this release of leukotrienes was blocked 
by the specific 5-1ipoxygenase inhibitor zileuton. 
Various  mediators  including  histamine,  platelet-activat- 
ing  factor,  prostaglandins,  thromboxane  A2,  and  leuko- 
trienes have been implicated in airway mucus release (37). 
Cysteinyl leukotrienes C4 and D 4 stimulate mucus secretion 
from cat  (38),  dog  (39),  and  guinea  pig  (40)  trachea  and 
bronchi in vivo and human bronchial explants in vitro (41, 
42).  We have demonstrated in mice that exogenous LTD4 
induces  airway  mucus  release  in  vivo.  When  compared 
with other mucus secretagogues for inducing release of mucus 
glycoproteins fi'om cultured human bronchial tissues, the rank 
order of potency (on a molar basis) is LTD4 ~>LTC  4 >mono- 
hydroxyeicosatetraenoic acids  >LTB  4 >PGA  2 =  PGD: = 
PGE1  =  PGF2~ =  PGI2 >histamine (37,  43, 44).  A striking 
finding of our study is that inhibition ofleukotriene forma- 
tion  prevents  allergen-induced  mucus  plugging  of mouse 
airways in vivo. These results suggest that leukotrienes play 
a major role in this mucus secretory process. 
LTB  4 is recognized as one of the most potent chemoat- 
tractants  for  leukocytes.  LTB  4  promotes  chemotaxis  and 
chemokinesis  of eosinophils  from  various  animal  species 
(45,  46) and humans (7, 47, 48).  In patients with nocturnal 
asthma,  the  increased  LTB  4 levels in  nocturnal  BAL fluid 
correlate significantly with the increased number of eosino- 
phils recovered in these samples (35).  The cysteinyl leuko- 
trienes  also  exert  potent  chemotactic  activity for  eosino- 
phils.  LTD4 promotes human eosinophil chemotaxis in vitro 
beginning at  10 -> M  (7).  The specific LTD  4 receptor an- 
tagonist MK-571  significantly reduces OVA-induced eosi- 
nophil influx into guinea pig conjunctiva in vivo 17 h after 
allergen challenge (49).  Inhalation ofLTE  4 in patients with 
asthma significantly increases the number of eosinophils re- 
covered in  the  airway lamnia propria 4  h  after LTE  4 chal- 
lenge (6). 
In our studies, inhibition ofleukotriene release by either 
a  5-1ipoxygenase  inhibitor  (zileuton)  or  FLAP  inhibitor 
(MK-886) was found to significantly inhibit eosinophil in- 
filtration  into  both  airway interstitial  tissue  and  the  BAL 
fluid indicating an important role for leukotrienes in medi- 
ating allergic airway infiltration by eosinophils,  a  key fea- 
ture  of asthma.  However,  these data  dissociate the  airway 
eosinophilic  influx  from the  increased  airway responsive- 
ness  to  methacholine.  Although  leukotriene  inhibition 
markedly reduced  the  eosinophil  infiltration,  such  inhibi- 
tion did not affect the bronchial hyperresponsiveness. 
Other studies in both rats and mice have also  suggested 
that BAL eosinophilia may be dissociated from airway hy- 
perresponsiveness.  When  mononuclear  cells  isolated  from 
peribronchial  lymph  nodes  from  OVA-sensitized  Brown 
Norway rats were transferred to naive syngeneic recipients, 
the  recipient  rats  after OVA  aerosol  challenge  developed 
late asthma responses (50).  In recipients of either sensitized 
or sham-sensitized mononuclear cells,  the  number of BAL 
fluid eosinophils  increased  at 32  h.  A  negative correlation 
between the  number of BAL fluid eosinophils and airway 
responsiveness to methacholine was observed in these stud- 
ies (50).  In OVA-sensitized BALB/c mice, airway hyperre- 
sponsiveness to  acetylcholine  and  an  influx  of eosinophils 
into the BAL fluid was observed 24 h  after the last aerosol 
challenge  with  OVA  (51).  Although  treatment  with  anti- 
IL-5  mAb  during  the  systemic  immunization  period  de- 
creased BAL fluid eosinophils from 44 to 2%,  no effect on 
the  airway response to acetylcholine was seen  (51).  These 
results contrast, however, with studies employing IL-5 de- 
ficient  mice  in  which  eosinophilia  was  closely  correlated 
with airway reactivity (52).  Whereas,  airway hyperreactiv- 
ity to methacholine and airway eosinophilia were absent in 
aeroallergen-challenged OVA-sensitized IL-5 deficient mice, 
airway eosinophilia and hyperreactivity were restored with 
reconstitution of IL-5 production (52).  Differences in con- 
clusions regarding the role of eosinophils in airway respon- 
siveness may be specific to the different antigen sensitization/ 
immunization  protocols  and  animal  species  employed  in 
these  studies.  Further,  many mechanisms  other  than  leu- 
kotriene  release  could  potentially  mediate  the  observed 
puhnonary function changes (e.g.,  alteration in smooth mus- 
cle contractility', neuropeptides,  muscarinic receptor defects) 
(53-55). 
Our  studies  indicate  that  leukotriene  inhibitors  have  a 
marked antiinflammatory effect on allergic lung inflamma- 
tion  in  an animal model that  reproduces many of the  fea- 
tures  of human  asthma.  These  antiinflammatory  actions 
may prove useful  in  the  therapy  of asthma  and  other  in- 
flammatory diseases. 
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